ConductScience.org, home

Paper · 28126011

References128

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112471242Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.Science2002https://conductscience.org/library/papers/12471242PubMed
217062558Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.Cancer Res2006https://conductscience.org/library/papers/17062558PubMed
320363874
AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation.
Mol Endocrinol2010https://conductscience.org/library/papers/20363874PubMed
414601044The IGF-1 receptor in cancer biology.Int J Cancer2003https://conductscience.org/library/papers/14601044PubMed
519221486Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells.Cell Cycle2009https://conductscience.org/library/papers/19221486PubMed
617085648Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium.Clin Cancer Res2006https://conductscience.org/library/papers/17085648PubMed
723942093Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.Clin Cancer Res2013https://conductscience.org/library/papers/23942093PubMed
819440038Metformin induces unique biological and molecular responses in triple negative breast cancer cells.Cell Cycle2009https://conductscience.org/library/papers/19440038PubMed
923663483Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.BMC Cancer2013https://conductscience.org/library/papers/23663483PubMed
1017355113The transcription factor nuclear factor-kappa B and cancer.Clin Oncol (R Coll Radiol)2007https://conductscience.org/library/papers/17355113PubMed
1121540236Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.Cancer Res2011https://conductscience.org/library/papers/21540236PubMed
1217712357AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.Nat Rev Mol Cell Biol2007https://conductscience.org/library/papers/17712357PubMed
1322643892Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.Nat Commun2012https://conductscience.org/library/papers/22643892PubMed
1425556614The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.Chin J Cancer2015https://conductscience.org/library/papers/25556614PubMed
1516286006mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.Cell2005https://conductscience.org/library/papers/16286006PubMed
1620234352mTOR signaling and drug development in cancer.Nat Rev Clin Oncol2010https://conductscience.org/library/papers/20234352PubMed
1725421433Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro.Oncol Rep2015https://conductscience.org/library/papers/25421433PubMed
1818212742The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.Oncogene2008https://conductscience.org/library/papers/18212742PubMed
1915314020Upstream and downstream of mTOR.Genes Dev2004https://conductscience.org/library/papers/15314020PubMed
2024644001Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.Clin Cancer Res2014https://conductscience.org/library/papers/24644001PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/28126011/references